However, we cannot exclude the possibility that increased auto-phosphorylation after imgatuzumab or cetuximab treatment activates other downstream pathways of EGFR with unknown effects on NSCLC cells [23]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.